<DOC>
	<DOCNO>NCT01617018</DOCNO>
	<brief_summary>PSOBIOTEQ national multicentric prospective cohort cutaneous psoriasis patient receive systemic treatment ( biotherapy DMARDs ) moderate severe cutaneous psoriasis . It result merge two study share study population address different objective : PSOBIO , develop academic dermatologist epidemiologist support National Drug Agency ( AGENCE NATIONALE DE SECURITE DU MEDICAMENT ET DES PRODUITS DE SANTE , ANSM ) ministry health ( PHRC 2009 ) focus safety issue , Pso-TEQ , develop industrials request French Transparency Commission ( HAUTE AUTORITE DE SANTE ) focus utilisation issue . The overall general objective PSOBIO ass `` real life '' safety efficacy biotherapies treatment cutaneous psoriasis comparison major conventional systemic therapy Pso-TEQ descriptive objective concern modality use biological therapy `` real life '' long-term benefit .</brief_summary>
	<brief_title>Assessing Long Term Effectiveness Safety Biotherapies Treatment Cutaneous Psoriasis</brief_title>
	<detailed_description>PSOBIOTEQ national multicentric prospective cohort , include patient receive systemic treatment ( biotherapy DMARDs ) moderate severe cutaneous psoriasis . The exposure interest exposure biological therapy : infliximab , adalimumab , etanercept , ustekinumab biotherapy enter market . The nature systemic treatment well administration modality define investigator accord usual practice . All dermatology department locate French metropolitan area use biotherapies treatment cutaneous psoriasis solicit participation cohort . The inclusion last least 3 year follow-up least 5 year patient ( 8 year maximum ) , 6 month periodicity data collection ( comply good clinical practice patient ) . Follow-up duration may extend case identification safety signal early year . Each study within cohort specific endpoint accord specific objective whole data require collected time study register single database ( eCRF ) . The statistical analysis perform clinical investigation epidemiology center ( INSERM CIE 801 ) BICHAT hospital 's department epidemiology clinical research 2 636 patient include follow distribution : . - Non-exposed group : 1200 patient - Exposed group : 1436 patient ( naive ) least 1200 patient naive biotherapy .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Inclusion criterion : Patients age 18 year Having inform objective conduct research sign write informed consent participate Consulting hospitalize cutaneous psoriasis ( clinical diagnosis ) justify prescription major systemic therapy cutaneous psoriasis main reason systemic treatment belong one two follow group : Patients expose major conventional systemic therapy ( methotrexate cyclosporine , exclude biotherapies ) since least 3 month plan institute treatment biotherapy next 6 month : nonexposed group . Patients expose biological therapy ( infliximab , adalimumab , etanercept , ustekinumab biotherapy enter market ) : expose group . Exclusion criterion : Patients cutaneous psoriasis main reason systemic treatment : treatment justify psoriatic arthritis , concomitant Crohn 's disease ... ; Patients unable comply plan cohort monitoring whose followup expect difficult . Patient treatment give baseline identify ( Patient participate doubleblind trialinvolving biotherapies example ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Psoriasis ; Biological therapy ; Methotrexate ; Cyclosporine</keyword>
</DOC>